Digital Media Net - Your Gateway To Digital media Creation. News and information on Digital Video, VR, Animation, Visual Effects, Mac Based media. Post Production, CAD, Sound and Music
Categories: News

Clarify Medical Now Approved as a TRICARE® Participating Provider

  • Coverage Enables TRICARE Beneficiaries With Psoriasis and Eczema to Access the Clarify Home Phototherapy System
  • The Clarify System’s Patented Technology Enables Patients to Treat at Home or While Traveling With the Same Level of Control and Care That They Receive in the Clinic

 

SAN DIEGO–(BUSINESS WIRE)–Clarify Medical today announced that the Clarify Home Phototherapy System is now covered for TRICARE beneficiaries with psoriasis and eczema, effective immediately. TRICARE is the health care program for uniformed service members, retirees, and their families, with approximately 10 million beneficiaries globally.

The Clarify System, which has been cleared by the FDA, is indicated for localized phototherapeutic treatment of dermatologic conditions such as psoriasis, vitiligo, atopic dermatitis (eczema), seborrheic dermatitis and leukoderma on all skin types (I-VI). It is the first and only connected phototherapy system that uses an app on the patient’s own smartphone (iOS or Android) to manage the dose, frequency, and duration of targeted narrowband UVB (NB-UVB) light therapy; the System helps to ensure that patients receive the proper doses recommended by the American Academy of Dermatology in its published Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis and The Vitiligo Working Group Recommendations for NarrowBand Ultraviolet B Light Phototherapy Treatment of Vitiligo.

The treatment regimen is prescribed by the patient’s physician but monitored and controlled by the Clarify System, enabling patients to administer treatment with clinical precision and achieve clinical efficacy in the convenience of their homes. The connected system monitors dosing, adherence, compliance, patient progress and satisfaction.

The Clarify smartphone app syncs to a patented, lightweight, handheld device which guides patients through delivering targeted narrowband UVB phototherapy treatments for their specific skin conditions. All treatment records, including photographs and patient-reported outcomes, are available to both the patient and the physician and can be used for evaluation during follow-up visits. Clarify CarePartners, trained patient support personnel, act as the first line of support for patients – coaching them on the use of the system and encouraging treatment adherence – greatly reducing the burden of these functions on the physician’s practice.

“We are proud to be able to support our service men and women and their families,” said George Mahaffey, President & CEO of Clarify Medical. “This is another significant milestone for Clarify as we continue to work diligently to expand U.S. market access for the Clarify System.”

About Clarify Medical, Inc.

Clarify Medical is a private San Diego-based medical device company focused on developing innovative technology, products and services that improve care for people with chronic skin conditions. Its Clarify Home Light Therapy System is now available nationally in the U.S. Learn more at www.clarifymed.com.

Contacts

Media Contact:

Teddy Fulham, 626-823-6744

teddy@clarifymed.com

Staff

Recent Posts

IRS Can Reject Installment Agreements Based on Spending – Clear Start Tax Explains What Financial Statements Reveal

Tax professionals warn that everyday expenses and lifestyle choices can derail IRS payment plans before…

14 hours ago

Bloomia Holdings, Inc. Announces December 31, 2025 Financial Results and Updated Expiration Date for Rights Offering

MINNEAPOLIS, MN / ACCESS Newswire / February 13, 2026 / Bloomia Holdings, Inc. (Nasdaq:TULP) ("Bloomia…

14 hours ago

Aspire Biopharma Announces the Appointment of New Member to Its Board of Directors

New independent director Phillip Balatsos brings commercial and capital markets expertise to drive development patent-pending…

14 hours ago

Moolec Science Achieves One of the Highest Commercial-Scale GLA Concentrations From U.S. GLASO1 Crushing

WARWICK, UK / ACCESS Newswire / February 13, 2026 / Moolec Science Limited, a wholly-owned…

14 hours ago

FEG Celebrates 5 Years of Relentless DeFi Innovation and Community-Driven Growth

DUBAI, UAE / ACCESS Newswire / February 13, 2026 / $FEG emerged five years ago,…

14 hours ago